Sub-Total: $0.00
Advances in Identifying the Diagnostic Pitfalls and New Therapies in the Clinical Practice of CIDP
Complimentary
Enduring Webcast
Released on 8/25/26
Expires on 8/25/27
Take Me to the Event Registration
Program Description
This enduring webcast addresses the pathogenesis and guideline recommendations for CIDP, as well as the integration of newer therapies. The activity will focus on:
CIDP – It is an immune-mediated syndrome
Pathophysiology – CIDP has been associated with pathophysiologic mechanisms that are not fully understood and likely differ across patient groups, including T-cell and macrophage infiltration, B-cell involvement, and the complement pathway.
EAN/PNS Guidelines for the Diagnosis of CIDP – The 2021 EAN/PNS criteria for CIDP allow a better characterization of CIDP variants and more appropriate treatment for patients
Diagnostic pitfalls in CIDP – Diagnostic pitfalls in CIDP frequently lead to misdiagnosis rates as high as 30% to 50% in clinical practice.
- Clinical Pitfalls
- Electrodiagnostic (EDx) Pitfalls
- Laboratory and Imaging Pitfalls
Treatment/Management of CIDP – With multiple phenotypic variations in clinical presentation and diverse pathophysiological mechanisms, treatment of patients with CIDP is complex and typically tailored to the individual patient.
- Immunoglobulin (IgG) Treatment – Intravenous immunoglobulin (IVIG) 10%; GAMMAGARD LIQUID, also known as Kiovig, for CIDP
- Subcutaneous Immunoglobulin (SCIG) – SCIG is available in vials or pre-filled syringes (PFS) and can be administered via pump or manual injection to treat CIDP
- Plasma Exchange – Plasma exchange, also known as plasmapheresis, is a technique that replaces plasma in a patient’s blood
- Corticosteroid Treatment – Corticosteroid treatment may provide longer therapy-free remission compared with IVIG
- Neonatal Fc Receptor Antagonist – The FcRn is responsible for preventing IgG degradation by recycling circulating IgG
- Efgartigimod – First-in-class neonatal Fc receptor antagonist for the treatment of CIDP
- Batoclimab and nipocalimab are currently in phase 2 and 3 studies, respectively
- Complement Inhibitors – Complement activation serves as a link between the adaptive and innate immune systems, through the direct binding of receptors expressed on T cells, B cells, macrophages, and by modulating the function of dendritic cells
- Riliprubart – A novel complement C1S inhibitor, undergoing a proof-of-concept study in people with CIDP
- Other Treatment Options – Immunosuppressive and B-cell depletion therapies
Intended Audience
This activity is designed to meet the educational needs of neurologists, neuromuscular disease specialists, specialty nurse practitioners, specialty physician assistants, and other health care providers who manage patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Commercial Supporter
Supported by an educational grant from argenx US Inc.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Integrate information on the pathophysiology, EAN/PNS guideline recommendations, and diagnostic pitfalls of CIDP.
- Implement appropriate patient-specific factor-based and novel targeted therapies for CIDP
Accredited Providers
Jointly Accredited by Haymarket Medical Education and MedNet
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Haymarket Medical Education and MedNet. Haymarket Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Haymarket Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses Credit Designation
This activity is awarded 1.25 contact hours (based on 60 minutes per contact hour).
Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit. 1.25 hours.